Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31, 2026 subject to approval of the members at the ensuing ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals reported FY26 results with 9.10% YoY revenue growth to Rs. 704.48 crore and 6.74% YoY net profit growth to Rs. 87.89 crore. The Board has recommended a dividend of Rs. 1.80 per share (18% on face value of Rs. 10) for shareholder approval at the ensuing AGM. EPS for FY26 stood at Rs. 43.88 per share. The company aims to achieve Rs. 1,000 crore revenue in the next 3 years with 15-18% annual growth, driven by cardiac, diabetic, dermatology, and ENT segments. FII holding increased to 5.20% as of March 31, 2026.
The dividend recommendation signals financial stability and shareholder-friendly approach, though the payout ratio of approximately 4% remains modest. Positive earnings growth may support the stock price ahead of the dividend approval.